A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside

Vaccine
Paul B ChapmanPhilip O Livingston

Abstract

In previous studies, we showed that immunization with 2.5 mg of BEC2, an anti-idiotypic MAb that mimics GD3 ganglioside, can induce antibodies against GD3 in approximately 25% of patients. In this trial, 50 melanoma patients at high risk for recurrence were randomly assigned to one of the five BEC2 dose levels (2.5 microg-10mg) to determine if lower or higher BEC2 doses are more immunogenic. We also tested whether prolonged booster immunizations can enhance the anti-GD3 antibody response. All patients developed detectable IgG against BEC2 except for one patient at the lowest BEC2 dose level. Six patients developed detectable antibody responses to GD3, all of them at the lower three dose levels of BEC2. We conclude that high doses of BEC2 are not necessary to induce anti-GD3 antibody responses and that lower doses may be more immunogenic than the 2.5 mg dose used in previous BEC2 trials. Prolonged booster immunizations did not induce or maintain antibody responses.

References

May 30, 1991·International Journal of Cancer. Journal International Du Cancer·G RitterP Livingston
Jul 1, 1991·The Journal of Clinical Investigation·P B Chapman, A N Houghton
May 15, 1985·International Journal of Cancer. Journal International Du Cancer·T TaiD L Morton
Aug 1, 1997·Melanoma Research·M L NasiP B Chapman

❮ Previous
Next ❯

Citations

Aug 17, 2012·Future Oncology·Catherine RabuLindy Durrant
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Sep 5, 2008·Expert Review of Vaccines·Lee B Riley, Sanjiv S Agarwala
Jun 23, 2011·Expert Review of Vaccines·Oliver KleinJonathan Cebon
May 1, 2009·Human Immunology·Marta E PolakIan A Cree
Feb 5, 2008·Biochimica Et Biophysica Acta·Takao TakiJacques Portoukalian
Jan 19, 2008·Cytotherapy·J-E ParkP B Chapman
Mar 5, 2013·Human Vaccines & Immunotherapeutics·Chizuru Ogi, Atsushi Aruga
Jul 30, 2014·Frontiers in Immunology·Thomas Kieber-EmmonsRamachandran Murali
Oct 10, 2006·Veterinary Immunology and Immunopathology·R J MilnerJ Farese
Jun 3, 2005·Nature Reviews. Drug Discovery·Danielle H Dube, Carolyn R Bertozzi
Jul 26, 2013·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Takao Taki
Oct 8, 2009·Alternatives to Laboratory Animals : ATLA·Jarrod Bailey
Jun 6, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Martina M Uttenreuther-FischerPeter Fischer
Jul 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paul B ChapmanPhilip O Livingston

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.